Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.15 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.57 | — | 21.81 | 1.79 | 7.19 | 2.64 | 2.96 | 15.83 | 41.00 | 2.91 | 4.21 | 3.54 | — | 46.45 | 37.86 | 8.68 | 11.52 | 0.71 | 0.83 | 0.98 | 2.23 |
| — | — | +636.5% | -88.7% | -82.5% | -9.3% | -29.7% | +347.4% | — | -93.7% | -88.9% | -59.3% | — | +6421.5% | +4487.6% | +784.1% | +416.0% | +231.3% | -82.3% | — | -45.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -203.6% | — | -739.5% | -61.8% | -43.5% | -75.3% | -71.8% | -90.3% | -74.3% | -50.9% | -33.4% | -58.6% | -355.1% | -94.9% | -52.5% | -40.6% | -29.0% | -28.5% | -25.9% | -19.5% | -17.7% |
| — | — | -930.3% | +31.6% | +41.4% | -47.7% | -115.2% | -54.3% | +79.1% | +46.3% | +36.5% | -44.3% | -1124.5% | -232.7% | -102.5% | -107.7% | -63.9% | -49.0% | -24.1% | — | -38.1% | |
| ROA | -89.9% | -51.5% | -200.1% | -23.6% | -16.9% | -27.8% | -29.5% | -36.7% | -27.8% | -22.1% | -16.5% | -19.8% | -24.8% | -22.3% | -18.3% | -16.7% | -13.3% | -13.3% | -12.1% | -11.1% | -11.4% |
| — | -85.2% | -578.6% | +35.6% | +39.3% | -25.6% | -79.1% | -85.1% | -12.0% | +0.7% | +10.0% | -18.9% | -86.4% | -68.0% | -51.1% | -50.4% | -17.0% | -0.7% | +38.3% | +8.0% | -10.9% | |
| ROIC | -352.0% | -62.7% | -297.6% | -42.6% | -47.3% | -173.3% | -236.0% | -184.7% | -120.4% | -97.5% | -70.9% | -66.7% | -56.2% | -60.3% | -60.8% | -138.3% | -1254.2% | -594.4% | -261.5% | -201.6% | -824.1% |
| — | +63.8% | -26.1% | +76.9% | +60.7% | -77.9% | -233.0% | -176.9% | -114.1% | -61.7% | -16.5% | +51.8% | +95.5% | +89.9% | +76.7% | +31.4% | -52.2% | +99.2% | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.22 | — | 9.55 | 1.22 | 1.32 | 0.89 | 1.18 | 0.80 | 1.55 | 1.20 | 0.99 | 0.77 | — | 4.29 | 1.98 | 1.22 | 0.62 | 0.49 | 0.62 | 0.51 | 0.43 |
| — | — | +711.7% | +52.0% | -14.5% | -25.9% | +19.2% | +4.1% | — | -72.1% | -50.0% | -36.8% | — | +778.3% | +217.7% | +137.9% | +44.4% | +23.1% | +548.0% | — | +469.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.50 | 0.38 | 0.74 | 2.50 | 2.30 | 2.11 | 1.70 | 2.21 | 1.69 | 2.17 | 3.13 | 4.29 | 1.66 | 2.15 | 3.28 | 4.53 | 2.50 | 3.05 | 3.01 | 3.44 | 10.08 |
| — | -82.0% | -56.6% | +12.7% | +36.4% | -2.4% | -45.7% | -48.4% | +1.8% | +1.0% | -4.6% | -5.3% | -33.9% | -29.6% | +9.0% | +31.5% | -75.2% | -57.7% | -52.9% | -44.0% | +55.8% | |
| Quick Ratio | 2.50 | 0.38 | 0.74 | 2.50 | 2.30 | 2.11 | 1.70 | 2.21 | 1.69 | 2.17 | 3.13 | 4.29 | 1.66 | 2.15 | 3.28 | 4.53 | 2.50 | 3.05 | 3.01 | 3.44 | 10.08 |
| — | -82.0% | -56.6% | +12.7% | +36.4% | -2.4% | -45.7% | -48.4% | +1.8% | +1.0% | -4.6% | -5.3% | -33.9% | -29.6% | +9.0% | +31.5% | -75.2% | -57.7% | -52.9% | -44.0% | +55.8% | |
| Interest Coverage | -125.87 | — | -1204.17 | — | — | -170.09 | -66.45 | -54.92 | -31.09 | -24.73 | -20.48 | -18.86 | -17.19 | -20.35 | -21.20 | -20.07 | -22.00 | -18.76 | -24.50 | -16.87 | -17.56 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TPST stock.
Tempest Therapeutics, Inc.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Tempest Therapeutics, Inc.'s business trajectory between earnings reports.